These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 29759629)
1. Circadian Variation of Ventricular Arrhythmias in Catecholaminergic Polymorphic Ventricular Tachycardia. Miyake CY; Asaki SY; Webster G; Czosek RJ; Atallah J; Avasarala K; Rao SO; Thomas PE; Kim JJ; Valdes SO; de la Uz C; Wang Y; Wehrens XHT; Abrams D JACC Clin Electrophysiol; 2017 Nov; 3(11):1308-1317. PubMed ID: 29759629 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Roses-Noguer F; Jarman JW; Clague JR; Till J Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Miyake CY; Webster G; Czosek RJ; Kantoch MJ; Dubin AM; Avasarala K; Atallah J Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):579-87. PubMed ID: 23667268 [TBL] [Abstract][Full Text] [Related]
4. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846 [TBL] [Abstract][Full Text] [Related]
5. Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy. Maron BJ; Semsarian C; Shen WK; Link MS; Epstein AE; Estes NA; Almquist A; Giudici MC; Haas TS; Hodges JS; Spirito P Heart Rhythm; 2009 May; 6(5):599-602. PubMed ID: 19332391 [TBL] [Abstract][Full Text] [Related]
6. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267 [TBL] [Abstract][Full Text] [Related]
7. Circadian variation of sustained ventricular tachycardia in patients with coronary artery disease and implantable cardioverter-defibrillators. Lampert R; Rosenfeld L; Batsford W; Lee F; McPherson C Circulation; 1994 Jul; 90(1):241-7. PubMed ID: 8026004 [TBL] [Abstract][Full Text] [Related]
8. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974 [TBL] [Abstract][Full Text] [Related]
9. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report. Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868 [TBL] [Abstract][Full Text] [Related]
11. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612 [TBL] [Abstract][Full Text] [Related]
12. Circadian pattern of spontaneous ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Eksik A; Akyol A; Norgaz T; Aksu H; Erdinler I; Cakmak N; Alper AT; Cinar B; Yildirim A; Gürkan K Med Sci Monit; 2007 Sep; 13(9):CR412-416. PubMed ID: 17767121 [TBL] [Abstract][Full Text] [Related]
13. Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. Inoue YY; Aiba T; Kawata H; Sakaguchi T; Mitsuma W; Morita H; Noda T; Takaki H; Toyohara K; Kanaya Y; Itoi T; Mitsuhashi T; Sumitomo N; Cho Y; Yasuda S; Kamakura S; Kusano K; Miyamoto Y; Horie M; Shimizu W Europace; 2018 Oct; 20(10):1675-1682. PubMed ID: 29309601 [TBL] [Abstract][Full Text] [Related]
14. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285 [TBL] [Abstract][Full Text] [Related]
15. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885 [TBL] [Abstract][Full Text] [Related]
16. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia. Heiner JD; Bullard-Berent JH; Inbar S Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070 [TBL] [Abstract][Full Text] [Related]
17. Circadian variations in the occurrence of ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. Kozák M; Krivan L; Semrád B Pacing Clin Electrophysiol; 2003 Mar; 26(3):731-5. PubMed ID: 12698674 [TBL] [Abstract][Full Text] [Related]
18. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Leren IS; Saberniak J; Majid E; Haland TF; Edvardsen T; Haugaa KH Heart Rhythm; 2016 Feb; 13(2):433-40. PubMed ID: 26432584 [TBL] [Abstract][Full Text] [Related]
19. Circadian variation of ventricular arrhythmia recurrences after cardioverter-defibrillator implantation in patients with healed myocardial infarcts. Mallavarapu C; Pancholy S; Schwartzman D; Callans DJ; Heo J; Gottlieb CD; Marchlinski FE Am J Cardiol; 1995 Jun; 75(16):1140-4. PubMed ID: 7762501 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature. Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]